At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25,565 enrolled
Drug / intervention
Levonorgestrel-releasing IUD +1 moredevice
Likely dose
Not stated in record
Key inclusion· 2
- ✓Cases: women with breast cancer diagnosis who are younger than 50 years at cancer diagnosis
- ✓Controls: women without breast cancer diagnosis who are younger than 50 years at interview
Key exclusion· 1
- ✕Unwilling to participate
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
Center for Epidemiology and Health Research, Germany·observational·Posted Apr 17, 2007·Updated Jan 25, 2016
In Brief
An observational study evaluating Levonorgestrel-releasing IUD and Copper IUD for Breast Cancer. Completed, enrolled 25,565 participants across 1 site.
Detailed Summary
The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGermany
CollaboratorsBayer
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedApr 2007
Primary CompletionMar 2014
TodayJul 2026
First PostedApr 17, 2007
Enrollment StartOct 1, 2006
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 19.2 years ago
Interventions
Levonorgestrel-releasing IUDdevice
This is a case-control-study; strictly speaking the category "intervention type" does not apply to this study.
Copper IUDdevice
This is a case-control-study; strictly speaking the category "intervention type" does not apply to this study.